IBDEI0L7 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10046,1,4,0)
 ;;=4^362.29
 ;;^UTILITY(U,$J,358.3,10046,2)
 ;;=^268619
 ;;^UTILITY(U,$J,358.3,10047,0)
 ;;=362.30^^44^560^40
 ;;^UTILITY(U,$J,358.3,10047,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10047,1,3,0)
 ;;=3^Hemiretinal Vein Occlusion
 ;;^UTILITY(U,$J,358.3,10047,1,4,0)
 ;;=4^362.30
 ;;^UTILITY(U,$J,358.3,10047,2)
 ;;=^105640
 ;;^UTILITY(U,$J,358.3,10048,0)
 ;;=362.37^^44^560^9
 ;;^UTILITY(U,$J,358.3,10048,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10048,1,3,0)
 ;;=3^CRVO-Partial
 ;;^UTILITY(U,$J,358.3,10048,1,4,0)
 ;;=4^362.37
 ;;^UTILITY(U,$J,358.3,10048,2)
 ;;=^268627
 ;;^UTILITY(U,$J,358.3,10049,0)
 ;;=362.50^^44^560^51
 ;;^UTILITY(U,$J,358.3,10049,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10049,1,3,0)
 ;;=3^Mac Degen,Senile/Atrophy
 ;;^UTILITY(U,$J,358.3,10049,1,4,0)
 ;;=4^362.50
 ;;^UTILITY(U,$J,358.3,10049,2)
 ;;=^73072
 ;;^UTILITY(U,$J,358.3,10050,0)
 ;;=362.70^^44^560^28
 ;;^UTILITY(U,$J,358.3,10050,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10050,1,3,0)
 ;;=3^Degen/Hered Disorder
 ;;^UTILITY(U,$J,358.3,10050,1,4,0)
 ;;=4^362.70
 ;;^UTILITY(U,$J,358.3,10050,2)
 ;;=^268650
 ;;^UTILITY(U,$J,358.3,10051,0)
 ;;=362.74^^44^560^91
 ;;^UTILITY(U,$J,358.3,10051,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10051,1,3,0)
 ;;=3^Retinitis Pigmentosa
 ;;^UTILITY(U,$J,358.3,10051,1,4,0)
 ;;=4^362.74
 ;;^UTILITY(U,$J,358.3,10051,2)
 ;;=^105693
 ;;^UTILITY(U,$J,358.3,10052,0)
 ;;=362.75^^44^560^50
 ;;^UTILITY(U,$J,358.3,10052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10052,1,3,0)
 ;;=3^Mac Degen,Juvenile
 ;;^UTILITY(U,$J,358.3,10052,1,4,0)
 ;;=4^362.75
 ;;^UTILITY(U,$J,358.3,10052,2)
 ;;=^268656
 ;;^UTILITY(U,$J,358.3,10053,0)
 ;;=362.76^^44^560^74
 ;;^UTILITY(U,$J,358.3,10053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10053,1,3,0)
 ;;=3^RPE Hypertrophy
 ;;^UTILITY(U,$J,358.3,10053,1,4,0)
 ;;=4^362.76
 ;;^UTILITY(U,$J,358.3,10053,2)
 ;;=^268657
 ;;^UTILITY(U,$J,358.3,10054,0)
 ;;=362.82^^44^560^85
 ;;^UTILITY(U,$J,358.3,10054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10054,1,3,0)
 ;;=3^Retinal Exudates
 ;;^UTILITY(U,$J,358.3,10054,1,4,0)
 ;;=4^362.82
 ;;^UTILITY(U,$J,358.3,10054,2)
 ;;=^268659
 ;;^UTILITY(U,$J,358.3,10055,0)
 ;;=363.12^^44^560^68
 ;;^UTILITY(U,$J,358.3,10055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10055,1,3,0)
 ;;=3^Periph Disem Choroiditis
 ;;^UTILITY(U,$J,358.3,10055,1,4,0)
 ;;=4^363.12
 ;;^UTILITY(U,$J,358.3,10055,2)
 ;;=^268675
 ;;^UTILITY(U,$J,358.3,10056,0)
 ;;=363.15^^44^560^1
 ;;^UTILITY(U,$J,358.3,10056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10056,1,3,0)
 ;;=3^AMPPE
 ;;^UTILITY(U,$J,358.3,10056,1,4,0)
 ;;=4^363.15
 ;;^UTILITY(U,$J,358.3,10056,2)
 ;;=^268678
 ;;^UTILITY(U,$J,358.3,10057,0)
 ;;=363.33^^44^560^96
 ;;^UTILITY(U,$J,358.3,10057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10057,1,3,0)
 ;;=3^Scars of Post Pole of Chorioret
 ;;^UTILITY(U,$J,358.3,10057,1,4,0)
 ;;=4^363.33
 ;;^UTILITY(U,$J,358.3,10057,2)
 ;;=^268681
 ;;^UTILITY(U,$J,358.3,10058,0)
 ;;=363.41^^44^560^97
 ;;^UTILITY(U,$J,358.3,10058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10058,1,3,0)
 ;;=3^Senile Atrophy of Choroid
 ;;^UTILITY(U,$J,358.3,10058,1,4,0)
 ;;=4^363.41
 ;;^UTILITY(U,$J,358.3,10058,2)
 ;;=^268686
 ;;^UTILITY(U,$J,358.3,10059,0)
 ;;=363.43^^44^560^4
 ;;^UTILITY(U,$J,358.3,10059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10059,1,3,0)
 ;;=3^Angioid Streaks
 ;;^UTILITY(U,$J,358.3,10059,1,4,0)
 ;;=4^363.43
 ;;^UTILITY(U,$J,358.3,10059,2)
 ;;=^7492
 ;;^UTILITY(U,$J,358.3,10060,0)
 ;;=363.50^^44^560^42
 ;;^UTILITY(U,$J,358.3,10060,1,0)
 ;;=^358.31IA^4^2
 ;;
 ;;$END ROU IBDEI0L7
